<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807023</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_8895_DeCiFer</org_study_id>
    <secondary_id>2020-A02454-35</secondary_id>
    <nct_id>NCT04807023</nct_id>
  </id_info>
  <brief_title>Decompensation of Cirrhosis and Iron Metabolism</brief_title>
  <acronym>DeCiFer</acronym>
  <official_title>Decompensation of Cirrhosis and Iron Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron is a crucial metal whose metabolism is tightly regulated. Iron deficiency or iron&#xD;
      overload are both deleterious at the cellular, organic and systemic levels. In line with the&#xD;
      major role of the liver in iron homeostasis, links between iron metabolism and acute on&#xD;
      chronic liver failure have been highlighted. Nevertheless, due to the difficulty of&#xD;
      accurately assessing iron metabolism in this situation, therapeutic intervention on iron&#xD;
      metabolism in this setting is currently not codified.&#xD;
&#xD;
      A better understanding of these mechanisms is therefore essential, in particular by&#xD;
      characterizing the impact of exposure to non-transferrin-bound iron in acute on chronic liver&#xD;
      failure on short-term mortality.&#xD;
&#xD;
      Overall, a better understanding of the physiopathological mechanisms of iron should allow to&#xD;
      optimize the martial balance in this condition and also improve therapeutic approaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of abnormal iron</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceruloplasmin ferroxidase activity</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin blood levels</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritinemia</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transferrinemia</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transferrin saturation coefficient</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of manganese</measure>
    <time_frame>days 0, 2, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of complications</measure>
    <time_frame>during hospitalization and a maximum of 28 days after admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial infection</measure>
    <time_frame>during hospitalization and a maximum of 28 days after admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fungal infection</measure>
    <time_frame>during hospitalization and a maximum of 28 days after admission</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>blood sampling</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with diagnosis of cirrhosis hospitalized for acute on chronic liver failure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old.&#xD;
&#xD;
          -  Diagnosis of cirrhosis, previously known or not, of any etiology, histologically&#xD;
             proven or not.&#xD;
&#xD;
          -  Hospitalization for acute on chronic liver failure:&#xD;
&#xD;
          -  Ascites decompensation.&#xD;
&#xD;
          -  Or spontaneous infection of the ascites fluid (defined as PNN &gt; 250/mm3 of ascites).&#xD;
&#xD;
          -  Or digestive hemorrhage related to portal hypertension (digestive fibroscopy showing&#xD;
             active bleeding or stigmas of recent bleeding from esophageal and/or gastric varices).&#xD;
&#xD;
          -  Or hepatic encephalopathy (clinically defined +/- increase in ammonia and/or by&#xD;
             electroencephalogram and classified in stages according to West-Haven).&#xD;
&#xD;
          -  Or hepato-renal syndrome (HRS-AKI criteria, EASL 2018).&#xD;
&#xD;
          -  Or bacterial infection (defined by a bacteremia identified by at least one blood&#xD;
             culture and/or an infectious site authenticated on imaging).&#xD;
&#xD;
          -  Or Acute Alcoholic Hepatitis (histologically proven or not).&#xD;
&#xD;
          -  Non-opposition of the patient, relative or legal representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with oral or intravenous iron in the month prior to hospitalization.&#xD;
&#xD;
          -  Implementation of a TIPS in the month prior to admission.&#xD;
&#xD;
          -  Presence of hepatocellular carcinoma with an expected survival &lt; 3 months or any other&#xD;
             progressive cancer.&#xD;
&#xD;
          -  Adult person subject to legal protection (safeguard of justice, curatorship,&#xD;
             guardianship), person deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giguet Baptiste</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mevel Nicolas</last_name>
    <phone>02 99 28 25 55</phone>
    <email>dri@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ganivet Anne</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GIGUET Baptiste</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decompensation of cirrhosis</keyword>
  <keyword>Iron metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

